Table 1.

Selected phases II and III trials of various agents for treatment of chemotherapy induced nausea and vomiting in patients undergoing multiday cisplatin based chemotherapy.

Study	Phase	N	CINV prophylaxis	Emesis		Nausea
				Day 1 CR	Days 1–5 CR
Einhorn et al., 1990 [14]	II	36	Ondansetron	77%	30%	NA
Sledge et al., 1992 [15]	III	45	Ondansetron versus metoclopramide	78% versus 14% (p < 0.001)	30% versus 9% (p = 0.002)	VAS scores 8 versus 58.5 (p < 0.001)
Bremer, 1992 [17]	III	200	Granisetron versus alizapride (substituted benzamide) + dexamethasone	90% versus 66% (p < 0.001)	49% versus 35%.	NA
Fox et al., 1993 [21]	III	45	Ondansetron + dexamethasone + chlorpromazine versus ondansetron	95% versus 82%	55% versus 32% (p = 0.22)	VAS scores 5.5 versus 15 (p = 0.046)
Noble et al., 1994 [18]	III	200	Ondansetron versus granisetron	NA	40% versus 44% Patient preference, 34% versus 26% (p = 0.048)	NA
Fauser et al., 2000 [22]	III	210	Dolasetron + dexamethasone versus dolasetron	NA	73% versus 41% (p < 0.0001). CR rates on each study day were also significantly higher (p = 0.029)	VAS score of 0 (no nausea) day 1: 88% versus 60% (p < 0.001); day 5: 63% versus 37% (p = 0.017)
Einhorn et al., 2007 [23]	II	41	Palonosetron + dexamethasone	88%	51%	No or mild nausea, self-reported 59%
Albany et al., 2012 [24]	III	69	Aprepitant + 5-HT3 RA (other than palonosetron) + dexamethasone versus aprepitant + dexamethasone	NA	47% versus 15% (p = 0.01)	VAS: aprepitant better than placebo on all 6 days
Hamada et al., 2014 [25]	II	30	Aprepitant + palonosetron + dexamethasone	NA	90%	Mild to no nausea 70%

CR: complete response (no emesis and no need for rescue medication); VAS: visual analog scale for nausea; 5-HT₃ RA: 5-hydroxytryptamine receptor antagonists; NA: not available.